18 December 2013
Intellectual Ventures – arguably the world’s most infamous NPE with around 70,000 IP assets – has developed its own ‘patent finder’ site to "help customers interested in buying or licensing assets from [its] portfolio". Is this the first step to patent licensing transparency? Or is it merely a reflex to the US’ impending ‘troll laws’? Either way, it’s a small step in the right direction – although it is also notable that only ‘the majority’ of IV’s portfolio is collated – why not all? Have certain ‘crown jewels’ or patents earmarked for litigation been withheld?
We can only hope, in the ultimate bid for transparency, that the remainder of the portfolio, as well as guideline licensing rates follow ...
- This news has also been picked up by IPKat, its take on the news is available here.
17 December 2013
E-commerce businesses, motor-related or otherwise, should take a look at the discussion of MFN clauses in the Competition Commission’s Provisional Findings Report in its private motor insurance investigation (see paras 68 onwards). This provisional report contains the first available reasoned finding by a competition authority in relation to MFNs in a real-life online context, assessing how they affect competition. The report makes an interesting distinction between narrow MFNs (a promise by a motor insurer to a price comparison website not to undercut prices on its own website) and wide MFNs (where the MFN promise extends to cover third party websites also). In general, the CC thinks that narrow MFNs do not restrict competition – except where the insurer has a strong brand and strong direct sales channel, whilst wide MFNs will soften price competition which can “lead to less entry, less innovation and higher commission fees, all leading to higher premiums.” Businesses, especially online businesses, engaged in negotiations over clauses like this will be wise to keep an eye on this aspect of the Competition Commission’s investigation.
13 December 2013
The ever controversial issue of the availability of injunctive relief for FRAND-encumbered SEPs took centre stage at the latest meeting of the ETSI IPR Special Committee (10-12 December 2013).
A number of network operators (‘NOs’) put forward a joint proposal on the circumstances in which injunctions can be sought/enforced. This is reported to have gained some traction in the discussions - in part as the NOs are seen to be relatively neutral in what has been a polarised debate. Some optimistic commentators have suggested that a consensus might be imminent. The ‘safe harbour’ proposal put forward by the NOs suggests amending the ETSI IPR Policy to provide that owners of FRAND-encumbered SEPs may seek and enforce injunctions only if the potential licensee does not agree to participate in / be bound by an adjudication process (court or arbitration). The proposal is silent as to the detail of how the adjudication process should be conducted and states that this is to be left to the discretion of the court/arbitrator.
An ETSI press release issued shortly after the meeting (here) states that ETSI members have “agreed to continue to explore these new contributions in a collaborative manner.... ahead of the next meeting planned on 18 to 20 February 2014”.
The proposal is likely to be welcomed by the Commission which has endorsed third party FRAND adjudication as an alternative to lengthy and costly patent litigation. The Commission has indicated that it considers that licensees that agree to third party adjudication are ‘willing licensees’ and so should not be subject to requests for injunctions (see for example a speech by Alexander Italianer Director General of DG COMP from 2013 here).
In addition, WIPO (after consultation with ETSI) has recently released tailored model arbitration and mediation submission agreements for FRAND disputes (more details can be found here).
Notwithstanding general support for the efforts of the NOs, it remains to be seen whether the NOs proposal is too ‘bare boned’ for ETSI members that want some legal certainty if they are to give up their right to seek an injunction (and also for those implementors who may feel constrained to engage in a third party adjudication process, with no real feel for likely scope, approach and process). For example, one of the most controversial (and important) issues is the extent to which the adjudication process should be conducted on a ‘per patent’ or ‘portfolio’ basis (the former is advocated by licensees and the latter by licensors unsurprisingly). Licensees argue that they do not want to be bound to pay royalties for patents that have not been upheld as valid and infringed whereas licensors argue that the adjudication process should mirror real life FRAND negotiations which are carried out on a portfolio basis and that a portfolio approach is the only way in which FRAND disputes can be resolved once and for all. The current proposal leaves this divisive issue to the discretion of the court/arbitrator – however this latitude may not be welcome to all. In this area, perhaps even more than in other areas of competition law controversy, the devil is inevitably going to be ‘in the detail’. Personally, I think there may be still some way to go before industry consensus will be reached (if ever) even though this appears to be a step in that direction.
12 December 2013
In its judgment, the Court ruled that, despite the high market share of the merged entity on the online consumer communication market, the transaction did not raise competition concerns.
It is worth reading this judgment side by side with earlier Microsoft tying decisions/judgments, in which Microsoft was considered to have abused a dominant position because of users’ preferences to use applications pre-loaded onto the operational system. One may wonder what led the Commission and the Court to approve a merger which would allow Microsoft to do exactly this.
The Commission’s and the Court’s answer is to point to the dynamic and innovative nature of the online consumer communication market, on which services are provided to users for free, allowing them to easily switch providers. As the merger analysis looks at the future conduct of the merged entity, the Commission and the Court (perhaps anticipating that this trend will continue into the future) had fewer objections to this merger than may have been the case a few years ago.
It remains to be seen if the Commission will follow the same approach in the Article 102 cases which focus on the past behaviour of the investigated entity. There are quite a few statements in the Court’s judgment suggesting that this approach could have a broader application outside the context of this transaction (e.g. paragraphs 69, 73, 79, 88, 92 and 96). The Commission is conducting a number of antitrust investigations in this area, so we may get some answers soon. Watch this space.
Sophie Lawrance and Damian Pietrzak
11 December 2013
On 5 December 2013, the US House of Representatives passed the Innovation Act (otherwise known as the Goodlatte Bill). The Act is widely considered to be, in part, an attempt to curb the practices of “patent trolls”. Key provisions include:
- increased pleading requirements for patent infringement claims;
- limitations on the extent of discovery required at early stages in litigation; and
- powers for the Court to order that the loser pays the prevailing party’s costs.
The behaviour of patent trolls has been the subject of intense scrutiny in the US following the publication of a White House Paper in June 2013 that was critical of the impact that patent trolls were having on the US economy. In addition to the Innovation Act, the Senate are also currently considering another piece of draft legislation – the Patent Transparency and Improvements Act – which is also considered to be an attempt to curb the behaviour of patent trolls. Furthermore, the FTC has requested input on its proposal to scrutinise the practices of patent trolls by posing a number of questions to a selection of trolls concerning their structures and practices. The deadline for responses is 16 December 2013. For more on the FTC study, see here.
We can expect the political and legal scrutiny of troll activity to continue well into the New Year.
10 December 2013
The 4th annual report on the Commission’s pharma patent monitoring exercise was published yesterday (here). The relative numbers of the different types of settlements (those which the Commission regards as non-problematic vs. those which restrict generic entry / include a “value transfer”) are not so very different from last year, at least once the effect of Portugal’s newly introduced Hatch Waxman-type regime is taken out of the equation.
Indeed, much of the text of the report is also very similar to previous years. However, there are a few important additions which appear to give an indication of some of the issues in the various cases that the Commission has been looking at. This is particularly useful information for the industry given the delayed public access to the Lundbeck decision.
Probably the most interesting part of this report compared with previous years are the aspects which indicate how the Commission views early entry type agreements. The Commission has not always been clear on how it views settlement agreements which split the difference between the date of the settlement agreement and the date of patent expiry. It has been assumed by some in the industry that the Commission views such settlements more favourably than those which limit the generic company’s entry until patent expiry. It appears that this is not – or not always – the case, unless the entry is immediate and not limited in any way (e.g. by any requirement to pay royalties, or by any constraints on the marketing of the generic company’s own product). See paragraph 11 of the report which clearly states: “agreements providing for an early entry of a generic medicine will be seen as limiting generic entry where entry is not immediate”. This approach is followed up in the analysis of the BII settlements (i.e. those that the Commission regards as most likely to attract competition law scrutiny) which distinguishes a number of settlements of in which the “value transfer” element consists of early entry and licence granted to the generic company.
However, paragraph 13 also notes that in some cases “an early entry may be pro-competitive when compared to the parties’ anticipated outcome of the litigation”. This is new to the report, and demonstrates that the Commission intends to infer the likely outcome of the litigation from the companies’ internal or other contemporaneous statements about the likely outcome. (This is surely open to gaming – companies involved in patent litigation now have an incentive to make over-inflated statements of confidence in order to try to support their belief that they would have won the litigation. In our view, a more appropriate point of comparison would be the actual context of the agreement, e.g. whether the generic has a marketing authorisation, is actually ready to enter immediately or not, although even in that case it should not follow axiomatically that any settlement agreement including restrictions and a value transfer will be unlawful.)
Other new aspects worth noting are as follows:
- The wide definition of the concept of “value transfer” continues, with the example of the purchase of stocks from the generic at market price being explicitly listed (see paragraph 12). It appears that this practice is drawn from one of the Lundbeck agreements that the Commission held infringed Article 101 earlier this year (the press release announcing the decision against Lundbeck stated that the company: “purchased generics' stock for the sole purpose of destroying it”);
- There are a number of new references to the treatment of non-assertion clauses under which the patentee promises not to assert the patent, but does not specifically grant a licence. These references do not sit easily with the sections describing the treatment of immediate entry settlements (as discussed above). Contrary to the favourable view of immediate entry settlements, non-assertion clauses “may be perceived as constituting a value transfer” as “the generic gained marketable value”. Although the report suggests that such agreements may not attract “the highest degree of antitrust scrutiny”, this is of little comfort to the parties to such an agreement in an age of private competition law actions, and given the potential unenforceability of such agreements.
- The Commission also responds to commentary suggesting that its policy will force companies to litigate to the bitter end, suggesting that the number of settlement agreements and the high proportion which are unproblematic in the Commission’s eyes means that there is no such problem. This is difficult to assess fully without access to the settlement agreements themselves, but it is very likely that the majority of the settlement agreements in the A category (no restrictions imposed) in particular are not true settlements of litigation which remains contested, but rather discontinuations by the patentee. There is a suggestion of this in the note in paragraph 37 which refers to the proportion of settlements concerning expired patents. Similarly, B1 settlements appear to involve the generic simply giving up and accepting to be bound by the patent.
The inconsistencies noted above suggest that even after a sector inquiry and four rounds of reports, a number of issues in this space still remain to be fully worked out even to make the Commission’s own internal policy fully coherent. Given the recent appeals announced by the parties to the Lundbeck agreements, the General Court will eventually have the opportunity to look at the Commission’s approach. However, it is likely to be a number of years before a clear view emerges.
9 December 2013
Competition policy and its relationship with IP is the regulators’ topic of the moment. EU Commissioner Almunia chimed in today (9 December - see here) following the comments of FTC Commissioner Ohlhausen on 4 December (see here). Regulatory humility was the theme of one of the speeches; the other was quicker to advocate competition law intervention to remedy perceived defects in other mechanisms (in the case in point, where SSOs are said not to be acting quickly to limit recourse to injunctive relief for SEPs). Both mentioned the need for restraint and care in enforcement given possible ramifications for investment and innovation. However, the views of the two as to when intervention is appropriate/necessary appear to diverge. The tone and content of the speeches were markedly different and they are worth reading side by side to appreciate the distinctions. In sum, it seems likely that significant enforcement on IP issues in the EU will continue.
6 December 2013
An NPE, Cascades, has accused a group of handset manufacturers of entering into a collective 'boycott' of licensing negotiations. The collusion is alleged to have been orchestrated via RPX, which has been described as “a defensive patent aggregator – an “anti-troll” – formed to protect its members from NPEs”. See: “Anti-Patent Troll” Fails to Secure Dismissal of Amended Antitrust Complaint.
As if the antitrust analysis in the ' patent wars' wasn't complex enough...
6 December 2013
In November 2013, Commissioner Almunia delivered a speech at the London School of Economics entitled “Competition in the Online World”. Almunia set out his perception of the importance of competition law enforcement in the online sector, noting that “what happens in the online world today has important implications for virtually every other sector in the digital economy.” Clearly as he moves into the final months of his term, Almunia is keen to stress the significance of the online world.
Following his speech, on 5 December 2013, the Commission confirmed that it had initiated unannounced inspections in several Member States at the premises of a number of retailers of consumer electronic products and small domestic appliances. According to it press release found here, the Commission suspects that the companies in question may have put in place restrictions on online sales which may be anti-competitive.
The Commission’s focus on online sales is mirrored by national competition authorities. A number of authorities are particularly watching this space, including Germany’s Bundeskartellamt and the UK’s OFT. In its Annual Plan for 2013-14, the OFT stated that it would “continue to focus on online sales channels” on the basis that “online commerce brings many benefits for consumers and contributes to innovation and economic growth, but may also remain a significant area of potential consumer detriment.
6 December 2013
I attended a Kings College lecture given by Professor Richard Whish yesterday. Prof Whish gave a typically well-argued presentation designed to provoke the rehabilitation of Article 101(3) as a basis for competition law exemption. His suggestion (which he has also made to members of the DG Comp) is that more reasoned non-infringement decisions should be reached, in which Article 101(3) is applied, particularly in relation to matters such as online selling which (the world having moved on) are not addressed in any of the corpus of pre-self-assessment case law.
I can’t say I’m optimistic that the Commission will find the resources (and political willpower) to go in this direction. Article 101(3) looks set to remain the last refuge of the desperate for some time to come…